We're Hopeful That Prescient Therapeutics (ASX:PTX) Will Use Its Cash Wisely
Prescient Therapeutics Receives AU$2.4 Million R&D Tax Rebate; Shares Down 4%
Prescient Therapeutics (ASX:PTX) received AU$2.4 million in research and development tax incentive for fiscal 2023, according to a Tuesday news release. Shares of the oncology company declined 4% in r
FDA Grants Prescient Therapeutics (ASX:PTX) Broad Orphan Drug Status for PTX-100 Cancer Treatment
Prescient Therapeutics (ASX:PTX) Shareholders Have Earned a 31% CAGR Over the Last Three Years
No Data